º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Redundancies expected at Thermo Fisher Scientific's Cramlington site

Around 79 jobs are reported to be at risk as the company confirmed 'adjustments' to its workforce in line with demand

Thermo Fisher Scientific's Cramlington site(Image: Handout)

Job cuts are expected at a North East maker of laboratory equipment.

Thermo Fisher Scientific, which makes a range of products including lab containers and sterile liquids, has confirmed it intends to make "adjustments" to its staffing levels at its Cramlington facility. It says the move is in response to lower demand.

Around 79 jobs are understood to be at risk as the firm says consultations with staff are now under way. It comes after reports that Thermo Fisher has also scaled back operations at some of its test making facilities in San Diego, California.

Read more: North East automotive supply chain welcomes JLR gigafactory announcement

A spokesperson for the company said: "Thermo Fisher Scientific continuously evaluates its global operations to identify opportunities to improve efficiency and effectiveness in meeting our customers’ needs. There are times when we must adjust staffing levels to remain in line with macro-economic conditions and current volume demands.

"In alignment with this ongoing effort, we have made the decision to propose the adjustment of staffing levels at our Cramlington, º£½ÇÊÓÆµ site to remain in line with current manufacturing volume demands. Further information regarding this proposal will be available once works council negotiations are completed.

"Decisions that may impact colleagues and their families are never taken lightly. However, these proposed actions are designed to better help us serve our customers, strengthen our global competitive position, and provide long-term growth and success of our organization."

Thermo Fisher has headquarters in Massachusetts and runs a number of facilities across the º£½ÇÊÓÆµ. In first quarter 2023 results published earlier this year, the company said revenue declined 9% to $10.71bn. Meanwhile GAAP (generally accepted accounting principles) operating income for the first quarter of 2023 was $1.56bn, compared with $2.82bn the year previously.